NASDAQ · CDTTW

CDT Equity Inc.

$0.01 +$0.00 (+14.00%) 1D

Key Metrics

$3
Market cap
P/E · TTM
Revenue · TTM
−$39.22M
Net income
EPS · TTM $-135,723.18
Dividend yield
Free cash flow
Beta · 1Y -1.02
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 3
    The stock moved +74.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 3
  • Jun 2
    From its May 29 high, the share price fell 57%.

    Peak close $0.02 on May 29; trough close $0.01 on Jun 2. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -57%
  • May 6
    The stock moved +65.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.01 – $0.02
Avg volume · 20D44.6K
Net cash
Book value / share$-24,809.69
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About CDT Equity Inc.
IPO dateSep 25, 2023
Employees4

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 561.8% · —

Financial Health

Current ratio0.34
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$8.44M

Cash Flow · TTM

Operating CF −$15.56M
Capex
Free cash flow
Buybacks $106.00K
Dividends paid
Shareholder yield 3,217,386.0%

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings